{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:49:12Z","timestamp":1789685352414,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute\/National Institutes of Health","award":["K07-CA20103"],"award-info":[{"award-number":["K07-CA20103"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Comparative Effectiveness Research on Cancer in Texas","award":["RP140020"],"award-info":[{"award-number":["RP140020"]}]},{"name":"NIH T32","award":["CA101642"],"award-info":[{"award-number":["CA101642"]}]},{"name":"Cancer Center Support","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ygyno.2018.06.020","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T05:22:45Z","timestamp":1530249765000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness"],"prefix":"10.1016","volume":"150","author":[{"given":"Larissa A.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy S.","family":"Suidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Dottino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Alejandro Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ygyno.2018.06.020_bb0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9990","key":"10.1016\/j.ygyno.2018.06.020_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.020_bb0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2011.08.030","article-title":"Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer","volume":"123","author":"Thrall","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.020_bb0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamaoncol.2016.4411","article-title":"Overall survival following Neoadjuvant chemotherapy vs primary Cytoreductive surgery in women with epithelial ovarian Cancer: analysis of the National Cancer Database","volume":"3","author":"Rauh-Hain","year":"2017","journal-title":"JAMA Oncol."},{"issue":"31","key":"10.1016\/j.ygyno.2018.06.020_bb0025","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2011.35.9935","article-title":"Is the easier way ever the better way?","volume":"29","author":"Chi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.020_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.06.020_bb0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/IGC.0b013e31828cd7e0","article-title":"The \u201cdefinitive\u201d trial of surgical cytoreduction in advanced-stage ovarian cancer","volume":"23","author":"Naik","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.020_bb0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2018.06.020_bb0045","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1200\/JCO.2016.68.1239","article-title":"Use and effectiveness of Neoadjuvant chemotherapy for treatment of ovarian Cancer","volume":"34","author":"Meyer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2018.06.020_bb0050","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2016.69.7458","article-title":"How to select Neoadjuvant chemotherapy or primary Debulking surgery in patients with stage IIIC or IV ovarian carcinoma","volume":"34","author":"Vergote","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"8 Suppl","key":"10.1016\/j.ygyno.2018.06.020_bb0055","first-page":"IV","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"issue":"12","key":"10.1016\/j.ygyno.2018.06.020_bb0060","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.ygyno.2018.06.020_bb0065","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/01.mlr.0000223480.52713.b9","article-title":"Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients","volume":"44","author":"Klabunde","year":"2006","journal-title":"Med. Care"},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.020_bb0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2011.03.022","article-title":"Trends in treatment of advanced epithelial ovarian cancer in the Medicare population","volume":"122","author":"Thrall","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.020_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","article-title":"Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients","volume":"98","author":"Earle","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"19","key":"10.1016\/j.ygyno.2018.06.020_bb0080","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2018.06.020_bb0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J. Am. Stat. Assoc."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.020_bb0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/AOG.0b013e31822a6d56","article-title":"Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly","volume":"118","author":"Thrall","year":"2011","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.020_bb0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2015.08.015","article-title":"Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)","volume":"139","author":"Seifert","year":"2015","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T03:40:13Z","timestamp":1534822813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818310023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0090825818310023"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}